Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial-Reference-Cited by-同舟云学术

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial

Published:2019-05 Issue: Volume:112 Page:57-65
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Yuan Peng,Hu Xichun,Sun Tao,Li Wei,Zhang Qingyuan,Cui Shude,Cheng Ying,Ouyang Quchang,Wang Xiaojia,Chen Zhendong,Hiraiwa Masahide,Saito Kenichi,Funasaka Setsuo,Xu Binghe

Funder

Eisai Co., Ltd., Japan

Eisai Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2012

2. National comprehensive cancer network clinical Practice guidelines in Oncology (NCCN Guidelines®). Breast cancer,2018

3. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer;Twelves;Crit Rev Oncol Hematol,2016

4. Extending survival with chemotherapy in metastatic breast cancer;O'Shaughnessy;Oncol,2005

5. Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane;Saji;BioDrugs,2013

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States;ESMO Open;2024-09

2. Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer;Frontiers in Pharmacology;2024-07-11

3. Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study;Cancer Communications;2024-06-28

4. Eribulin in breast cancer: Current insights and therapeutic perspectives;World Journal of Experimental Medicine;2024-06-20

5. Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer;Journal of the College of Physicians and Surgeons Pakistan;2024-06-01